Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2007

01-10-2007 | Epidemiology

Psychometric properties of the simplified Chinese version of the EORTC QLQ-BR53 for measuring quality of life for breast cancer patients

Authors: Chonghua Wan, Xueliang Tang, Xin M. Tu, Changyong Feng, Susan Messing, Qiong Meng, Xiaoqing Zhang

Published in: Breast Cancer Research and Treatment | Issue 2/2007

Login to get access

Abstract

A Simplified Chinese version of the EORTC QLQ-BR53 was evaluated using responses from 233 patients with breast cancer in China by assessing the construct and criterion-related validity, internal consistency and test–retest reliability, and responsiveness as measured by score changes of the scales. Internal consistency reliability measured by Cronbach’s coefficient α is greater than 0.75 for most multi-item scales except cognitive functioning (0.41) and breast symptoms (0.71). Test–retest reliability coefficients for all domains are greater than 0.80 with the exception of physical functioning (0.65), social functioning (0.75), appetite loss (0.75), diarrhea (0.72), and body image (0.72). Correlation and factor analysis among domains and items showed good construct validity for both QLQ-C30 and QLQ-BR23. Score changes over time were observed in most domains except emotional functioning, global health status/QOL, dyspnoea, constipation, diarrhea, financial difficulties, sexual functioning, sexual enjoyment, and breast symptoms. Therefore, the Simplified Chinese version of QLQ-BR53 shows reasonable validity, reliability, and responsiveness and can be used to measure QOL for Chinese patients with breast cancer.
Literature
1.
Society AC (2000). Cancer facts and figures-2000. Atlanta
2.
Coebergh JWW, Janssen-Heijnen MLG, Louwman WJ et al (2001) Cancer incidence and survival in the South of the Netherlands,1955–1999 and incidence in the North of Belgium, 1996–1998. Comprehensive Cancer Centre South (IKZ), Eindhoven
3.
Selby PJ, Champon JA, Etazadi-Amoli J et al (1984) The development of a method for assessing the quality of life of cancer patients. Br J Cancer 50(1):13–22PubMed
4.
Brade MJ, Cella DF, Mo F et al (1997) Reliability and validity of the functional assessment of cancer therapy-Breast quality-of- life instrument. J Clin Oncol 15(3):974–986
5.
Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale development and validation of the general measure. J Clin Oncol 11(3):570–579PubMed
6.
Aaronson NK, Cull A, Kaasa S et al (1994) The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology. Int J Ment Health 23(2):75–96
7.
Sprangers MA (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14(10):2756–2768PubMed
8.
Van der Steeg AFW, De Vries J, Roukema JA (2004) Quality of life and health status in breast carcinoma. EJSO 30:1051–1057PubMedCrossRef
9.
Kim S, Hays RD, Birbeck GL et al (2003) Responsiveness of the Quality of Life in Epilepsy Inventory (QOLIE-89) in an Antiepileptic Drug Trial. Qual Life Res 12(2):147–155PubMedCrossRef
10.
Kosinski M, Bjorner JB, Ware Jr JE et al (2003) The Responsiveness of Headache Impact Scales Scored Using ‘Classical’ and ‘Modern’ Psychometric Methods: A Re-analysis of Three Clinical Trials. Qual Life Res 12(8):903–912PubMedCrossRef
11.
Yun YH, Bae SH, Kang IO et al (2004) Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer (EORTC) Breast-Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). Support Care Cancer 12(6):441–445PubMedCrossRef
12.
Chie WC, Chang KJ, Huang CS, Kuo WH (2003) Quality of life of breast cancer patients in Taiwan: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. Psychooncology 12(7):729–735PubMedCrossRef
13.
Montazeri A, Harirchi I, Vahdani M et al (2000) The EORTC breast cancer-specific quality of life questionnaire (EORTC QLQ-BR23): translation and validation study of the Iranian version. Qual Life Res 9(2):177–184PubMedCrossRef
Metadata
Title
Psychometric properties of the simplified Chinese version of the EORTC QLQ-BR53 for measuring quality of life for breast cancer patients
Authors
Chonghua Wan
Xueliang Tang
Xin M. Tu
Changyong Feng
Susan Messing
Qiong Meng
Xiaoqing Zhang
Publication date
01-10-2007
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9443-1

Other articles of this Issue 2/2007

Breast Cancer Research and Treatment 2/2007 Go to the issue

Epidemiology

Breast cancer risk factors and second primary malignancies among women with breast cancer

Preclinical Study

Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma

Review Paper

Provider’s volume and quality of breast cancer detection and treatment

Review

Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature

Research Paper

Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Preclinical Study

Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits